150 results on '"Tsuboi, Akihiro"'
Search Results
2. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs
3. An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
4. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy
5. Identification of mouse helper epitopes for WT1-specific CD4+ T cells
6. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides
7. Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer
8. A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
9. WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives
10. Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT
11. Enhancement of Efficacy of Wilms’ Tumor Gene WT1 Product-derived Peptide Cancer Vaccine by Co-administration with Immunopotentiating Agents: Lessons from Mouse Models
12. The activated conformation of integrin [beta]7 is a novel multiple myeloma-specific target for CAR T cell therapy
13. Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments
14. WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
15. T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy
16. An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
17. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
18. Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients
19. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response
20. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain
21. WT1 epitope‑specific IgG and IgM antibodies for immune‑monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine
22. Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer
23. T cell-intrinsic vitamin A metabolism and its signaling are targets for memory T cell-based cancer immunotherapy
24. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children
25. Polycythemia Vera Associated with Pulmonary Hypertension and Diffuse Large B-Cell Lymphoma: A Case Report
26. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy
27. Imaging Assessment of Tumor Response in the Era of Immunotherapy
28. Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects
29. Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies
30. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review
31. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides
32. Reader‑free ELISPOT assay for immuno‑monitoring in peptide‑based cancer vaccine immunotherapy
33. IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS’ TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS
34. Identification of mouse helper epitopes for WT1-specific CD4+ T cells.
35. A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
36. Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides
37. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity
38. WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies
39. The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy
40. Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse
41. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy
42. Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients
43. Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
44. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells
45. Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis
46. A Zbtb7a proto‐oncogene as a novel target for miR‐125a
47. An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells
48. IMCT-09WT1 PEPTIDE VACCINATION FOR GLIOMAS; SURVIVALS, BIOMARKERS AND RESPONSE ASSESSMENT
49. Wilms tumour 1 peptide vaccine as a cure‐oriented post‐chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.
50. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.